Neurol. praxi. 2024;25(2):151-154 | DOI: 10.36290/neu.2024.023

Ataxia telangiectasia or life in imbalance

MUDr. Sandra Vorlíčková
Oddělení dětské neurologie, Fakultní Thomayerova nemocnice, Praha

Ataxia-telangiectasia (AT) is an autosomal recessively disorder characterized by slowly progressive cerebellar ataxia, telangiectasia and heightended sensitivity to ionizing radiation. The condition often leads to immunodeficiency, presenting as recurrent respiratory infections. Other clinical manifestations may include oculomotor apraxia or extrapyramidal symptoms. Furthermore, patients are predisposed to hematological malignancies and solid tumors. In children under the age of 10, AT represents the most prevalent cause of progressive ataxia. This article aims to raise awareness of AT, providing an overview of its diagnosis and available options for symptomatic therapy. To illustrate these aspects, I present two case reports from our department.

Keywords: cerebellar degeneration, oculocutaneous telangiectasia, immunodeficiency, cancer susceptibility, radiation toxicity.

Accepted: April 10, 2024; Published: April 16, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vorlíčková S. Ataxia telangiectasia or life in imbalance. Neurol. praxi. 2024;25(2):151-154. doi: 10.36290/neu.2024.023.
Download citation

References

  1. Aeskulab [online, cit 29. 8. 2022]. Available from: https://www.aeskulab.cz/cs.
  2. Carranza D, Torres­‑Rusillo S, Ceballos­‑Pérez G, et al. Reconstitution of the Ataxia­‑Telangiectasia Cellular Phenotype With Lentiviral Vectors. Front Immunol. 2018;20;9:2703. doi: 10.3389/fimmu.2018.02703. Go to original source... Go to PubMed...
  3. Covarrubias AJ, Perrone R, Grozio A, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. doi: 10.1038/s41580-020-00313-x. Go to original source... Go to PubMed...
  4. Gatti R, Perlman S. Ataxia­‑Telangiectasia. 1999 Mar 19 [Updated 2016 Oct 27]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [online]. Seattle (WA): University of Washington, Seattle; 1993-2022. [Cit. 27. 11. 2022]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK26468/.
  5. Good Clinical Practice Network. [online, cit. 27. 11. 2022]. Available from: https://ichgcp.net/index.php/cs/clinical­‑trials­‑registry/NCT04870866.
  6. Greenberger S, Berkun Y, Ben­‑Zeev B, et al. Dermatologic manifestations of ataxia­‑telangiectasia syndrome. J Am Acad Dermatol. 2013;68(6):932-6. doi: 10.1016/j.jaad.2012. 12. 950. Go to original source...
  7. Chun HH, Sun X, Nahas SA, Teraoka S, et al. Improved diagnostic testing for ataxia­‑telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab. 2003;80(4):437-43. doi: 10.1016/j.ymgme.2003. 09. 008. PMID: 14654357. Go to original source...
  8. Mallott J, Kwan A, Church J, et al. Newborn screening for SCID identifies patients with ataxia telangiectasia. J Clin Immunol. 2013;33:540-9. doi: 10.1007/s10875-012-9846-1. Go to original source... Go to PubMed...
  9. Menkes JH, Sarnat HB, Maria BL. Dětská neurologie - II. díl. Praha Triton 2011, s. 1321; ISBN 978-80-7387-341-7.
  10. Národní screeningové centrum [online, 29. 8. 2022]. Available from: https://nsc.uzis.cz/.
  11. Nissenkorn A, Levy­‑Shraga Y, Banet­‑Levi Y, et al. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79:889-894. Availabler from: https://doi.org/10.1038/pr.2016. 19. Go to original source...
  12. Opal P. Ataxia­‑teleangiectasia. UpToDate 2022. [Cit. 29. 8. 2022]. Available from: https://www.uptodate.com/contents/ataxia­‑telangiectasia?search=ataxie%20teleangiekt%C3%A1zie & source=search_result & selectedTitle=7~150 & usage_type=default & display_rank=7.
  13. Riboldi GM, Samanta D, Frucht S. Ataxia Telangiectasia. [Updated 2022 Jul 4]. In: StatPearls [online]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. [Cit. 27. 11. 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519542/.
  14. Spring K, Ahangari F, Scott SP, et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia­‑telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002 Sep;32(1):185-90. doi: 10.1038/ng958. Go to original source... Go to PubMed...
  15. Syllaba L, Henner K. Contribution à l'étude de l'indépendance de l'athétose double idiopathique et congénitale. Atteinte familiale, syndrome dystrophique, signe du résau vasculaire conjonctival, intégrité psychique. Revue neurologique. 1926;1:541-560.
  16. Veenhuis SJG, van Os NJH, Janssen AJWM, et al. Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia. Mov Disord. 2021;12: 2951-2957. doi.org/10.1002/mds.28788. Go to original source... Go to PubMed...
  17. Verhagen M, Alfen N, Pillen S, et al. Neuromuscular Abnormalities in Ataxia Telangiectasia: A Clinical, Electrophysiological and Muscle Ultrasound Study. Neuropediatrics. 2007;38(3):117-121. doi:10.1055/s-2007-985899. Go to original source... Go to PubMed...
  18. Yang B, Dan X, Hou Y, et al. NAD+ supplementation prevents STING­‑induced senescence in ataxia telangiectasia by improving mitophagy. Aging Cell. 2021;20(4):e13329. doi: 10.1111/acel.13329. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.